Results 31 to 40 of about 54,678 (274)
EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia
Epigenetics, 2019 EZH2 is overexpressed in poor-prognostic chronic lymphocytic leukaemia (CLL) cases, acting as an oncogene; however, thus far, the EZH2 target genes in CLL have not been disclosed.Subazini Thankaswamy Kosalai, Mohammad Hamdy Abdelrazak Morsy, Nikos Papakonstantinou, Larry Mansouri, Niki Stavroyianni, Chandrasekhar Kanduri, Kostas Stamatopoulos, Richard Rosenquist, Meena Kanduri +8 moredoaj +1 more sourceEzh2 Inhibits Replicative Senescence of Atrial Fibroblasts Through Promotion of H3K27me3 in the Promoter Regions of CDKN2a and Timp4 Genes
Journal of Inflammation Research, 2022 Yingze Li,* Guojian Fang,* Wei Cao,* Jiali Yuan,* Shuai Song, Hong Peng, Yuepeng Wang, Qunshan Wang Department of Cardiology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200092, People’s ...Li Y, Fang G, Cao W, Yuan J, Song S, Peng H, Wang Y, Wang Q +7 moredoaj Review: Targeting EZH2 in neuroblastoma
Cancer Treatment Reviews, 2023 Neuroblastoma is one of the commonest extra-cranial pediatric tumors, and accounts for over 15% of all childhood cancer mortality. Risk stratification for children with neuroblastoma is based on age, stage, histology, and tumor cytogenetics. The majority of patients are considered to have high-risk neuroblastoma, for which the long-term survival is ...Jinhui Gao, Claire Fosbrook, Jane Gibson, Timothy J. Underwood, Juliet C. Gray, Zoë S. Walters +5 moreopenaire +2 more sourcesChromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer
, 2022 Background: The Nuclear Factor of Activated T-cells 1 (NFATc1) transcription factor and the methyltransferase Enhancer of Zeste Homolog 2 (EZH2) significantly contribute to the aggressive phenotype of pancreatic ductal adenocarcinoma (PDAC).Gaedcke, Jochen, Neesse, Albrecht, Forster, Teresa, Kopp, Waltraut; 1Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany; shilpapatil528@gmail.com (S.P.); kristina.reutlinger@med.uni-goettingen.de (K.R.); wkopp@med.uni-goettingen.de (W.K.); lennart.versemann@t-online.de (L.V.); jspitali@med.uni-goettingen.de (J.S.); shiv.singh@med.uni-goettingen.de (S.K.S.); volker.ellenrieder@med.uni-goettingen.de (V.E.); albrecht.neesse@med.uni-goettingen.de (A.N.), Patil, Shilpa, Ellenrieder, Volker, Singh, Shiv K., Neesse, Albrecht; 1Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany; shilpapatil528@gmail.com (S.P.); kristina.reutlinger@med.uni-goettingen.de (K.R.); wkopp@med.uni-goettingen.de (W.K.); lennart.versemann@t-online.de (L.V.); jspitali@med.uni-goettingen.de (J.S.); shiv.singh@med.uni-goettingen.de (S.K.S.); volker.ellenrieder@med.uni-goettingen.de (V.E.); albrecht.neesse@med.uni-goettingen.de (A.N.), Reutlinger, Kristina; 1Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany; shilpapatil528@gmail.com (S.P.); kristina.reutlinger@med.uni-goettingen.de (K.R.); wkopp@med.uni-goettingen.de (W.K.); lennart.versemann@t-online.de (L.V.); jspitali@med.uni-goettingen.de (J.S.); shiv.singh@med.uni-goettingen.de (S.K.S.); volker.ellenrieder@med.uni-goettingen.de (V.E.); albrecht.neesse@med.uni-goettingen.de (A.N.), Singh, Shiv K.; 1Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany; shilpapatil528@gmail.com (S.P.); kristina.reutlinger@med.uni-goettingen.de (K.R.); wkopp@med.uni-goettingen.de (W.K.); lennart.versemann@t-online.de (L.V.); jspitali@med.uni-goettingen.de (J.S.); shiv.singh@med.uni-goettingen.de (S.K.S.); volker.ellenrieder@med.uni-goettingen.de (V.E.); albrecht.neesse@med.uni-goettingen.de (A.N.), Forster, Teresa; 2Department of Gastroenterology, Endocrinology, Metabolism and Clinical Infectiology, Philipps University Marburg, 35043 Marburg, Germany; terry.forster@web.de, Hessmann, Elisabeth; 1Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany; shilpapatil528@gmail.com (S.P.); kristina.reutlinger@med.uni-goettingen.de (K.R.); wkopp@med.uni-goettingen.de (W.K.); lennart.versemann@t-online.de (L.V.); jspitali@med.uni-goettingen.de (J.S.); shiv.singh@med.uni-goettingen.de (S.K.S.); volker.ellenrieder@med.uni-goettingen.de (V.E.); albrecht.neesse@med.uni-goettingen.de (A.N.), Kopp, Waltraut, Spitalieri, Jessica; 1Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany; shilpapatil528@gmail.com (S.P.); kristina.reutlinger@med.uni-goettingen.de (K.R.); wkopp@med.uni-goettingen.de (W.K.); lennart.versemann@t-online.de (L.V.); jspitali@med.uni-goettingen.de (J.S.); shiv.singh@med.uni-goettingen.de (S.K.S.); volker.ellenrieder@med.uni-goettingen.de (V.E.); albrecht.neesse@med.uni-goettingen.de (A.N.), Ströbel, Philipp; 3Clinical Research Unit KFO5002, University Medical Center Goettingen, 37075 Goettingen, Germany; jochen.gaedcke@med.uni-goettingen.de (J.G.); philipp.stroebel@med.uni-goettingen.de (P.S.), Ströbel, Philipp, Cavestro, Giulia Martina, Hessmann, Elisabeth, Ellenrieder, Volker; 1Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany; shilpapatil528@gmail.com (S.P.); kristina.reutlinger@med.uni-goettingen.de (K.R.); wkopp@med.uni-goettingen.de (W.K.); lennart.versemann@t-online.de (L.V.); jspitali@med.uni-goettingen.de (J.S.); shiv.singh@med.uni-goettingen.de (S.K.S.); volker.ellenrieder@med.uni-goettingen.de (V.E.); albrecht.neesse@med.uni-goettingen.de (A.N.), Patil, Shilpa; 1Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany; shilpapatil528@gmail.com (S.P.); kristina.reutlinger@med.uni-goettingen.de (K.R.); wkopp@med.uni-goettingen.de (W.K.); lennart.versemann@t-online.de (L.V.); jspitali@med.uni-goettingen.de (J.S.); shiv.singh@med.uni-goettingen.de (S.K.S.); volker.ellenrieder@med.uni-goettingen.de (V.E.); albrecht.neesse@med.uni-goettingen.de (A.N.), Reutlinger, Kristina, Versemann, Lennart, Gaedcke, Jochen; 3Clinical Research Unit KFO5002, University Medical Center Goettingen, 37075 Goettingen, Germany; jochen.gaedcke@med.uni-goettingen.de (J.G.); philipp.stroebel@med.uni-goettingen.de (P.S.), Spitalieri, Jessica, Versemann, Lennart; 1Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany; shilpapatil528@gmail.com (S.P.); kristina.reutlinger@med.uni-goettingen.de (K.R.); wkopp@med.uni-goettingen.de (W.K.); lennart.versemann@t-online.de (L.V.); jspitali@med.uni-goettingen.de (J.S.); shiv.singh@med.uni-goettingen.de (S.K.S.); volker.ellenrieder@med.uni-goettingen.de (V.E.); albrecht.neesse@med.uni-goettingen.de (A.N.) +24 morecore +2 more sourcesZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer
Cell Reports, 2018 Summary: Although EZH2 enzymatic inhibitors have shown antitumor effects in EZH2-mutated lymphoma and ARID1A-mutated ovarian cancer, many cancers do not respond because EZH2 can promote cancer independently of its histone methyltransferase activity. Here Peijing Zhang, Zhenna Xiao, Shouyu Wang, Mutian Zhang, Yongkun Wei, Qinglei Hang, Jongchan Kim, Fan Yao, Cristian Rodriguez-Aguayo, Baochau N. Ton, Minjung Lee, Yumeng Wang, Zhicheng Zhou, Liyong Zeng, Xiaoyu Hu, Sarah E. Lawhon, Ashley N. Siverly, Xiaohua Su, Jia Li, Xiaoping Xie, Xuhong Cheng, Liang-Chiu Liu, Hui-Wen Chang, Shu-Fen Chiang, Gabriel Lopez-Berestein, Anil K. Sood, Junjie Chen, M. James You, Shao-Cong Sun, Han Liang, Yun Huang, Xianbin Yang, Deqiang Sun, Yutong Sun, Mien-Chie Hung, Li Ma +35 moredoaj +1 more source